Harbour Biomed announced that the Phase I clinical trial of B7H4x4-1BB bispecific antibody has completed the first patient dosing in the United States

Harbour Bio Pharmaceuticals (stock code: 02142.
HK) announced on October 20 that it has successfully completed the first patient in
the Phase I clinical trial of HBM7008, a bispecific antibody B7H4x4-1BB, in the United States.
The study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity
of HBM7008 in patients with solid tumors.

HBM7008, developed by its innovative immune cell adaptor HBICE^® platform, is an innovative bispecific antibody that simultaneously targets the tumor antigen B7H4 and the T cell co-stimulatory molecule 4-1BB, which specifically activates T cells and produces anti-tumor activity
only when bound to B7H4.
B7H4 is overexpressed in a variety of malignant solid tumors, including breast cancer, non-small cell lung cancer, ovarian cancer, and endometrial cancer
.
Due to its cross-link-dependent expression specificity and efficient immunomodulatory activity, HBM7008 has shown excellent safety and strong anti-tumor efficacy in preclinical studies, especially in mouse tumor models
.

Dr.
Jinsong Wang, Founder, Chairman and Chief Executive Officer of Harbour Bio Pharma, said, "We are pleased to complete the first patient dosing of B7H4x4-1BB in the United States, which is another milestone
in Harbour Bio Pharma's global leadership in next-generation immuno-oncology therapy innovation.
We are confident in
the potential of B7H4x4-1BB bispecific antibodies.
We will firmly adhere to the company's global innovation development strategy, efficiently promote this clinical research, and provide more innovative, effective and safe treatment options for patient treatment
.
" "

About HBM7008

HBM7008 is a bispecific antibody against tumor-associated antigen B7H4x4-1BB, which is highly dependent on cross-linking with T cell activation, so it has significant efficacy in co-stimulation and inhibition of tumor growth and improves safety
because it is highly dependent on tumor-associated antigen as mediated and cross-linked with T cell activation.
HBM7008 is a fully human bispecific antibody developed based on Harbour Health's innovative HBICE^® platform, and is currently the only bispecific antibody
against these two targets in the world.
Its unique tumor expression specificity and immunomodulatory activity are expected to produce better efficacy
in patients who are PD-L1-negative or resistant to PD-1/PD-L1 immunotherapy drugs.
With its novel biological mechanism of action and bispecific antibody design, it is expected to avoid the risk
of liver toxicity that may be caused by 4-1BB.